Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Clarient, Inc. (“Clarient” or the “Company”) (Nasdaq: CLRT) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by GE Healthcare (“GE”) in a transaction valued at approximately $580 million. Click here to learn how to join the action: http://www.rigrodskylong.com/news/ClarientInc-CLRT.
Under the proposed agreement, a subsidiary of GE will commence a cash tender offer for all outstanding common and preferred shares of Clarient at $5.00 per common share and $20.00 per preferred share, in each case payable in cash. GE will then acquire any Clarient shares not purchased in the tender offer in a second-step merger at the same price per share paid in the tender offer.
The investigation concerns whether Clarient’s board of directors failed to adequately shop the Company and obtain the best price possible for Clarient’s shareholders before entering into the agreement with GE. Indeed, shareholders holding approximately 47% of Clarient’s current outstanding voting stock have agreed, among other things, to tender their shares in the proposed transaction. Moreover, according to Yahoo! Finance, at least one analyst has set a price target of $6.00 per share for Clarient stock.
If you own the common stock of Clarient and purchased your shares before October 22, 2010, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at (888) 969-4242, or by e-mail to email@example.com.Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.